Circulating matrix metalloproteinase 3 due to myocardial ischemia

Heart Surgery Forum

Volumn 12, Issue 4, 2009, Pages

  Siminelakis, Stavros ^a   Kotsanti, Angeliki ^a   Kolaitis, Nicholas ^a   Niokou, Dimitra ^a   Vlachou, Ioanna ^a   Dimakopoulos, George ^a   Papadopoulou, Chrysanthy ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

STROMELYSIN; TROPONIN I; BIOLOGICAL MARKER;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; EXPERIMENTAL MODEL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; IN VIVO STUDY; LABORATORY TEST; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PREDICTOR VARIABLE; PRIORITY JOURNAL; RABBIT; REPERFUSION; TRACHEOTOMY; ANIMAL; BLOOD; ENZYMOLOGY;

ANIMALS; BIOLOGICAL MARKERS; MATRIX METALLOPROTEINASE 3; MYOCARDIAL ISCHEMIA; RABBITS;

EID: 70350456270     PISSN: 10983511     EISSN: 15226662     Source Type: Journal    
DOI: 10.1532/HSF98.20081152     Document Type: Article

References (21)

1. Abbott Laboratories. 1997. Abbott AXSYM System. Abbott Park, IL: Abbott Laboratories.
2. Abbott Laboratories. 2001. AxSYM System Operation Manual. Abbott Park, IL: Abbott Laboratories.
3. Ardelt P, Dorka P, Jaquet K, et al. 1998. Microanalysis and distribution of cardiac troponin I phospho species in heart areas. Biol Chem 379:341-7.
4. Bers DM. 2002. Cardiac Na/Ca exchange function in rabbit, mouse and man: What's the difference? J Mol Cell Cardiol 34:369-73.
5. Boyett MR, Jewell BR. 1978. A study of the factors responsible for rate-dependent shortening of the action potential in mammalian ventricular muscle. J Physiol 285:359-80.
6. Committee on Care and Use of Laboratory Animals. 1996. Guide for the care and use of laboratory animals. US Dept. of Health and Human Services Publ. No. 85-23. Bethesda, MD: National Institutes of Health.
7. Greemers EE, Cleutjens JP, Smits JF, Daemen MJ. 2001. Matrix metalloproteinase inhibition after myocardial infarction: review. Circ Res 89:201-10.
8. Iliodromitis EK, Kremastinos DT, Katritsis DG, Papadopoulos CC, Hearse DJ. 1997. Multiple cycles of preconditioning cause loss of protection in open-chest rabbits. J Mol Cell Cardiol 29:915-20.
9. Lindsey ML, Gannon J, Aikawa M, et al. 2002. Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction. Circulation 105:753-8.
10. Lorell BH, Isoyama S, Grice WN, Weinberg EO, Apstein CS. 1988. Effects of ouabain and isoproterenol on left ventricular diastolic function during low-flow ischemia in isolated, blood-perfused rabbit hearts. Circ Res 63:457-67.
11. Lu L, Gunja-Smith Z, Woessner JF, et al. 2000. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol Heart Circ Physiol 279:601-9.
12. Marian AJ, Wu Y, Lim DS, et al. 1999. A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest 104:1683-92.
13. Ogata Y, Enghild JJ, Nagase H. 1992. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267:3581-4.
14. Okada Y, Takeuchi N, Tomita K, Nakanishi I, Nagase H. 1989. Immunolocalization of MMP-3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis 48:645-53.
15. Okubo N, Hombrouck C, Fomes P, et al. 2000. Cardiac troponin I and myocardial contusion in the rabbit. Anesthesiology 93:811-7.
16. Romanic AM, Burns-Kurtis CL, Gout B, Berrebi-Bertrand I, Ohlstein EH. 2001. Matrix metalloproteinase expression in cardiac myocytes following myocardial infarction in the rabbit. Life Sci 68:799-814.
17. Samnegard A, Silveria A, Tornvall P, Hamsten A, Ericsson CG, Eriksson P. 2006. Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 259:530-6.
18. Sanbe A, James J, Tuzcu V, et al. 2005. Transgenic rabbit model for human troponin I-based hypertrophic cardiomyopathy. Circulation 111:2330-8.
19. Spinale FG. 2002. Matrix metalloproteinases: regulation and dysregulation in the failing heart [review]. Circ Res 90:520-30.
20. Wu TC, Leu HB, Lin WT, Lin CP, Lin SJ, Chen JW. 2005. Plasma MMP-3 level is an independent prognostic factor in stable coronary artery disease. Eur J Clin Invest 35:537-45.
21. Yellon DM, Iliodromitis E, Latchman DS, et al. 1992. Whole body stress fails to limit infarct size in the reperfused rabbit heart. Cardiovasc Res 26:342-6.